Viking Therapeutics’ experimental pill helped patients lose 12.2 % of their body weight in just 13 weeks—better than Eli Lilly’s latest effort but still shy of Novo Nordisk’s own results. Yet it was Novo Nordisk’s shares that “popped,” underscoring how the race for obesity drugs can move markets in unexpected ways.
Subscribe
Stock Market
Weight Loss Diets
Why Novo Nordisk Stock Popped Today
Key Takeaways:
- Viking Therapeutics’ oral GLP-1 candidate, VK2735, produced a 12.2 % weight-loss average in 13 weeks.
- The outcome topped Eli Lilly’s most recent GLP-1 pill data.
- Novo Nordisk continues to report stronger weight-loss figures than Viking.
- Novo Nordisk’s stock price “popped” following Viking’s announcement.
- The competition to dominate the oral GLP-1 weight-loss market is intensifying.
A Surprising Rally
News that a competitor’s pill had trimmed waistlines sent Novo Nordisk’s stock upward. The rally followed Viking Therapeutics’ disclosure that its experimental GLP-1 pill, VK2735, helped trial participants shed an average of 12.2 percent of their body weight over 13 weeks.
Viking’s Promising Numbers
“Viking Therapeutics says its new GLP-1 weight loss pill VK2735 helped patients shed 12.2 % of body weight in 13 weeks,” the company reported. The double-digit result instantly positioned Viking among the frontrunners in the booming obesity-drug field.
How the Rivals Stack Up
Viking’s figure, while impressive, “is a better result than Eli Lilly just reported for its GLP-1 pill,” according to the same report. Yet the data “not [is] quite as good as what Novo Nordisk reports,” leaving the Danish pharmaceutical giant as the benchmark for weight-loss efficacy.
Why Novo Nordisk Benefited
Investors appeared to interpret Viking’s success less as a threat and more as validation of the GLP-1 category that Novo Nordisk helped pioneer. The article’s headline—“Why Novo Nordisk Stock Popped Today”—captures the counter-intuitive reaction: stronger overall belief in the market can lift the leading incumbent even when a challenger posts strong results.
The Road Ahead
Viking’s head-turning 12.2 percent reduction sets a high bar for subsequent trials, while Eli Lilly and Novo Nordisk will continue refining their own regimens. For patients, the flurry of pills in development hints at more options; for investors, it signals that the battle for market share—and market valuation—is far from over.
